CN104119445A - Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof - Google Patents
Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof Download PDFInfo
- Publication number
- CN104119445A CN104119445A CN201310150884.4A CN201310150884A CN104119445A CN 104119445 A CN104119445 A CN 104119445A CN 201310150884 A CN201310150884 A CN 201310150884A CN 104119445 A CN104119445 A CN 104119445A
- Authority
- CN
- China
- Prior art keywords
- protein
- tag
- fusion protein
- peptide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 69
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 69
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 title claims abstract description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 title claims abstract description 5
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 230000003252 repetitive effect Effects 0.000 title abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 48
- 108700011893 Slit homolog 2 Proteins 0.000 claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 28
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 27
- 229920001184 polypeptide Polymers 0.000 claims abstract description 26
- 230000028327 secretion Effects 0.000 claims abstract description 23
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 104
- 102000004169 proteins and genes Human genes 0.000 claims description 96
- 210000004027 cell Anatomy 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 45
- 230000014509 gene expression Effects 0.000 claims description 31
- 239000013604 expression vector Substances 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 108091005804 Peptidases Proteins 0.000 claims description 14
- 239000004365 Protease Substances 0.000 claims description 14
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 11
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 108090001008 Avidin Proteins 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004901 leucine-rich repeat Anatomy 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 abstract description 5
- 210000004899 c-terminal region Anatomy 0.000 abstract description 4
- 238000005520 cutting process Methods 0.000 abstract description 4
- DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 238000002271 resection Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 77
- 239000012634 fragment Substances 0.000 description 19
- 102100027340 Slit homolog 2 protein Human genes 0.000 description 16
- 101150085024 Slit2 gene Proteins 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 238000000746 purification Methods 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 8
- 108010076818 TEV protease Proteins 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001042 affinity chromatography Methods 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000001742 protein purification Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004153 renaturation Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000723792 Tobacco etch virus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 108091033380 Coding strand Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101150018985 SLIT3 gene Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 102100027339 Slit homolog 3 protein Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010043945 Ephrin-A1 Proteins 0.000 description 1
- 102000020086 Ephrin-A1 Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101150097792 Robo1 gene Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004398 heart morphogenesis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses fusion protein containing a leucine-rich repetitive sequence, and a preparation method and application thereof. Concretely, the invention relates to fusion protein, and the fusion protein possesses the following structure from N terminal to C terminal: A-X-E-Y1-Y2 (formula Ia) or A-Y2-Y1-E-X (formula Ib), wherein A is an optional secretion signal peptide, X is a member rich in leucine repetitive sequence 1-2 (LRRs1-2) of Slit2 protein (neuronal guidance factor 2), E is a restriction enzyme cutting site, Y1 is a first tag peptide member, Y2 is a second tag short peptide member and the second tag short peptide member is His tag member, and '-' represents a peptide bond or a peptide joint for connecting the above members. The fusion protein is beneficial for correct folding of LRR (leucine-rich repeat) and forming active functional polypeptide, and is capable of simply removing two tag members through once resection enzyme cutting, thereby preparing high-purity high-activity LRR sequence.
Description
Technical Field
The invention relates to the field of biological molecules, in particular to a fusion protein containing leucine-rich repeat sequences, a preparation method and application thereof.
Background
The nerve-targeting factor Slit is a secreted extracellular matrix glycoprotein highly conserved evolutionarily, and its gene was found to play a role in the development of the central nervous system in 1988. Slit is one of a group of extracellular secreted proteins with a relative molecular mass of 170-190kDa, members of the axon-oriented family of molecules that direct axon growth and neuronal migration.
Slit protein is a multifunctional guide molecule serving as a ligand of roundabout (robo), and has functions of regulating the growth direction of neurite, guiding migration of nerve cells and influencing morphological differentiation of the nerve cells. Recent studies have found that Slit also plays a role in various physiological processes such as angiogenesis, cardiac morphogenesis, and tumor cell migration.
There are 3 Slit genes in vertebrates, namely Slit, Slit2, Slit3, and are widely expressed in various biological tissues.
The main structure of Slit protein includes an extracellular secretion signal peptide at the N-terminal, 4 consecutive leucine-rich repeats (LRRs), also designated as D1-D4 domains, 6-9 egf (epidermal growth factor) -like domains in tandem, a laminin G-like domain and a cysteine-rich C-terminal domain.
Slit2 can inhibit the migration of glioma, fibrosarcoma, breast cancer and oral squamous cell carcinoma cells, Slit3 can inhibit the migration of malignant melanoma cells, and Slit2 is reported to promote the metastasis of breast cancer and colorectal cancer cells. At present, the effect of Slit2 on angiogenesis is still controversial, and both effects of Slit2 on promoting angiogenesis and inhibiting angiogenesis are reported in documents. Dunaway et al found that Slit2, when present alone, demonstrated that it promoted angiogenesis in vitro and in vivo; however, in the presence of Ephrin-A1, Slit2 inhibited angiogenesis, indicating that the results obtained in a relatively simple in vitro cell assay environment do not completely reflect the actual effect in vivo.
The study of oil Prasad et al shows that the over-expression Slit2 can inhibit the growth of breast cancer cells and tumors in mice; studies by Tseng et al indicate that Slit2 can slow down the progression of lung cancer; Yuasa-Kawada et al reported that Slit protein can inhibit the migration of breast cancer cells; Werbowestski-Ogilvie et al reported that Slit2 inhibited the invasion of medulloblastoma cells; yiin et al reported that Slit2 inhibited the invasion of glioma cells in the brain. Comprehensively considers the loss of function caused by extensive promoter methylation of Slit2 and/or Robo1 genes in tumors and the inhibition effect of Slit2 on the tumorigenesis and development.
For research and application, it is necessary to express and separate and purify Slit protein or a fragment thereof. However, since the content of native proteins is limited and isolation is difficult, it is necessary to develop an efficient recombinant production process.
In recombinant production processes, it is often difficult to efficiently produce a protein of interest that is conformationally correct and that can be readily isolated and purified. Although the conventional E.coli expression system can express the target protein with high efficiency, the conventional E.coli expression system usually requires a complicated renaturation process, and the activity of the renatured target protein is often unsatisfactory.
When expressed using eukaryotic expression systems, while avoiding renaturation processes, correct folding of the protein of interest, how to achieve high expression levels, and how to efficiently isolate the protein of interest remain difficult, especially for certain short peptides or polypeptides containing repetitive sequences.
After the culture solution (or fermentation product) containing the target protein is obtained, various purification means can be used for separation and purification. At present, one commonly used method for separating and purifying recombinant proteins is affinity chromatography.
Taking the His tag as an example, 6 XHis is a tag protein specially designed for recombinant protein purification work, is the most common expression mode at present, has mature expression and purification technology and is relatively cheap, and has the advantages of convenient expression and no influence on the activity of the protein basically. Generally, proteins with histidine can be adsorbed by nickel sepharose or nickel NTA sepharose in a natural state, but since the His-tag is very small, if the His-tag is not easily exposed due to being folded into the protein during folding of the fusion protein, it is difficult to perform protein purification work; while the His tag does have the problem of insufficient specificity.
Generally, the purity of the protein obtained by separation by using the His tag technology is about 90%, but in the prior art, the process and the steps for further purifying the protein are relatively complicated, and the added protein or peptide segment often interferes with the activity of the target protein, so that the expression of the target protein is inaccurate or the impurities are excessive.
In view of the above, there is a strong need in the art to develop a simple and efficient production process for producing a recombinant protein with high purity and high activity.
Disclosure of Invention
The present invention aims to provide a method for producing a foreign protein efficiently and simply, thereby preparing a recombinant protein with high purity and high activity simply and efficiently.
The invention provides a fusion protein, which has a structure shown in formula Ia or Ib from N end to C end:
A-X-E-Y1-Y2 formula Ia;
A-Y2-Y1-E-X are of formula Ib;
wherein,
a is an optional secretion signal peptide;
x is a leucine-rich repeat1-2 (leucine-rich repeat1-2, LRR1-2) element of Slit2 protein;
e is a restriction enzyme site;
y1 is a first tag polypeptide element;
y2 is a second tag short peptide element which is a His tag element;
"-" denotes a peptide bond or a peptide linker connecting the above elements.
In another preferred embodiment, the fusion protein has a secretion signal peptide at the N-terminus.
In another preferred example, the secretion signal peptide is a secretion signal peptide from Slit2 or a secretion signal peptide from other proteins.
In another preferred embodiment, the secretion signal peptide has or does not have the starting amino acid Met at its N-terminus.
In another preferred embodiment, said first tag polypeptide element is 46 aa.
In another preferred embodiment, "-" between X and E is a peptide bond.
In another preferred embodiment, there is no protease cleavage site between Y1 and Y2.
In another preferred example, "-" between Y1 and Y2 is a peptide bond.
In another preferred embodiment, the cleavage site is that of TEV protease.
(LeuGluValLeuPheGlnGlyPro,SEQ ID NO.:3)
In another preferred embodiment, the peptide linker is 3-15 amino acids in length; preferably 5-10 amino acids.
In another preferred example, the Slit2 protein is derived from a mammal.
In another preferred example, the Slit2 protein is derived from human, rat and mouse; more preferably, it is of human origin.
In another preferred embodiment, Y1 comprises a modified avidin tag (Strap II tag) or streptavidin tag as shown in SEQ ID NO. 2.
In another preferred embodiment, the His tag element comprises an 8 × His tag element and a 6 × His tag element.
In another preferred embodiment, Y1 is a Strap II tag and Y2 is an 8 × His tag element.
In another preferred example, the amino acid sequence of the Slit2LRR1-2 is shown in SEQ ID No. 5.
In a second aspect of the invention, there is provided an isolated polynucleotide encoding a fusion protein according to the first aspect of the invention.
In another preferred embodiment, the polynucleotide sequence is as shown in SEQ ID No. 6.
In a third aspect of the invention, there is provided an expression vector comprising a polynucleotide according to the second aspect of the invention.
In another preferred embodiment, the expression vector comprises a eukaryotic expression vector and a prokaryotic expression vector.
In a fourth aspect of the invention, there is provided a host cell comprising an expression vector according to the third aspect of the invention or transfected with a polynucleotide according to the second aspect of the invention.
In another preferred embodiment, the host cell comprises a mammalian cell; preferably, CHO cells, 293 cells are included.
In a fifth aspect of the invention, a method for preparing a Slit2LRR1-2 protein is provided, and the method comprises the following steps:
(i) culturing a host cell according to the fourth aspect of the invention under suitable expression conditions such that the fusion protein according to the first aspect of the invention is expressed;
(ii) separating and purifying the fusion protein of the first aspect of the present invention from the culture system;
(iii) and carrying out enzymolysis on the fusion protein by using protease aiming at the element E to prepare Slit2LRR 1-2.
In another preferred embodiment, in step (ii), the first separation is performed by affinity chromatography against the Y1 element; a second separation was then performed using affinity chromatography against the Y2 element.
In another preferred example, in step (iii), the method further comprises separating Slit2LRR1-2 from the polypeptide E-Y1-Y2 or Y2-Y1-E to produce purified Slit2LRR 1-2.
In a sixth aspect of the invention, a method for preparing a Slit2LRR1-2 protein is provided, and the method comprises the following steps:
the fusion protein of the first aspect of the invention is subjected to enzymolysis by protease aiming at the element E, so as to prepare Slit2LRR 1-2.
In a seventh aspect of the invention, a purified Slit2LRR1-2 protein is provided, which is produced by the method of the fifth or sixth aspect of the invention.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Drawings
FIG. 1 is a map of the original pcDNA3.1(-) plasmid;
FIG. 2 shows a flow chart of a method for constructing an expression plasmid of a partial sequence of LRR1-2 domain of a eukaryotic expression Slit2 protein in example 1;
FIG. 3 is an RT-PCR amplification electrophoretogram of partial sequence of LRR1-2 domain of Slit2 protein;
FIG. 4 is a PCR amplification electrophoresis diagram of the Strap II protein tag, His protein tag and TEV restriction enzyme site sequence;
FIG. 5 is a map of the constructed pcDNA3.1(-)/Slit2LRR1-2 plasmid;
FIG. 6 is a protein expression profile of the constructed plasmid detected by Western Blot method.
Detailed Description
The present inventors have made extensive and intensive studies and have found, for the first time, that, surprisingly, the addition of a first tag polypeptide element and a second tag short peptide element to one end (particularly, the C-terminal) of an LRR sequence not only facilitates correct folding of the LRR to form an active functional polypeptide, but also enables both tag elements to be removed by a single enzyme digestion, thereby producing a high-purity and high-activity LRR sequence. The present invention has been completed based on this finding.
Term(s) for
As used herein, "protein of the invention", "fusion protein having formula Ia or Ib", all used interchangeably, refer to a fusion protein having formula Ia or Ib, which comprises, from N-terminus to C-terminus, an optional secretion signal peptide, a gene of interest, a cleavage site, a first tag polypeptide element, and a second tag short peptide element, respectively; or optionally a secretion signal peptide, a second tag short peptide element, a first tag polypeptide element, a cleavage site, and a gene of interest. The fusion protein has the remarkable characteristic that a continuous tandem tag element which can be removed by enzyme digestion is arranged at the C end or the N end. Furthermore, it is to be understood that the term also includes active fragments and derivatives of recombinant fusion proteins.
As used herein, "isolated" refers to a substance that is separated from its original environment (which, if it is a natural substance, is the natural environment). If the polynucleotide or polypeptide in the natural state in the living cell is not isolated or purified, but the same polynucleotide or polypeptide is isolated or purified if it is separated from other substances coexisting in the natural state.
As used herein, the terms "tag protein", "tag protein element", "tag element" and "tag element" are used interchangeably and all refer to a tag polypeptide that can be used for the isolation and purification of a fusion protein having formula Ia or Ib according to the invention.
Slit2 protein and LRR thereof
The full-length sequence of the Slit2 protein is shown as SEQ ID No. 13, and the nucleotide sequence for coding the protein is shown as SEQ ID No. 12. The sequence of the Slit2LRR1-2 protein is shown in SEQ ID No. 5, and the nucleotide sequence for coding the protein is shown in SEQ ID No. 4.
The Slit2 protein is derived from mammals, preferably from human, rats and mice.
As used herein, "Slit 2LRR1-2 protein" refers to the LRR1-2 domain of Slit2 protein.
As used herein, "purified Slit2LRR1-2 protein" means that the Slit2LRR1-2 protein is substantially free of other proteins, lipids, carbohydrates or other substances with which it is naturally associated. One skilled in the art can purify Slit2LRR1-2 protein using standard protein purification techniques. Substantially pure proteins produce a single major band on a non-reducing polyacrylamide gel.
Peptide bonds or peptide linkers
The elements of the fusion protein of the invention having formula Ia or Ib may be linked directly by peptide bonds or by peptide linkers. In a preferred embodiment of the present invention, the elements of the fusion protein having formula Ia or Ib are linked by peptide bonds to form a fusion protein.
In general, too short a peptide linker may cause steric hindrance inside the fusion protein, affecting the correct folding of the protein, and too long a peptide linker may increase the immunogenicity of the fusion protein, and may also affect the activity and function of the fusion protein. Thus, peptide linkers useful in the present invention typically comprise 3-15 amino acids; preferably 5-10 amino acids.
Fusion proteins with consecutive tandem tag elements
The amino-terminus (or carboxy-terminus) of the fusion protein of the invention comprises two tag elements (as shown in formula Ia or Ib) in series.
A-X-E-Y1-Y2 formula Ia
A-Y2-Y1-E-X formula Ib
Wherein A, X, E, Y1 and Y2 are as defined above.
For first tag polypeptide element Y1, preferred Y1 is selected from the group consisting of: modified avidin tag (StrapII tag) (length 46aa), streptavidin (Strep II tag) (length 9 aa).
The modified avidin tag (Strap II tag) is a tag protein modified on the basis of streptavidin (Strep II tag), the polypeptide sequence of the tag protein is shown as SEQ ID No. 2, and the nucleotide sequence for encoding the polypeptide is shown as SEQ ID No. 1.
The purification of the Strap II tag of the invention and the Strep II tag may be the same or substantially the same, i.e.by chromatography with affinity for biotin. The Strap II tag (SEQ ID No.:2) increases the affinity of the tag compared to the Strep II tag, which has the advantage that the purification process is performed under physiological conditions, and the mild elution of desthiobiotin used protects the activity of the target protein. Furthermore, the need for a blocking treatment step is avoided with conventional Strep II tag purification techniques.
Y2 is a second tag short peptide element and is a His tag element. His tag elements useful in the present invention include 6 XHis or 8 XHis short peptides, preferably 8 XHis tag elements.
In addition, there is no protease cleavage site between Y1 and Y2, and they are directly linked by peptide bond.
The protein expression scheme of the continuous tandem tags has the advantages of combining two carriers to avoid existing problems on one hand, and can optimize the protein purification steps to improve the purity of the purified protein and reduce the pollution from animal sources and ionic pollution in the purification process as much as possible on the other hand.
In the fusion protein of the present invention, protease cleavage sites are located between elements Y1 and X, and may include cleavage sites commonly used in the art for isolating and purifying proteins, such as TEV protease, Hrv3C protease. With the proviso that the cleavage site is not included in the sequence of the other elements of the fusion protein of the present invention.
The TEV protease is a 50kDa protease derived from the Nla protease of Tobacco Etch Virus (TEV) after modification, and is designed to have better stability than the natural TEV protease. This protease was used to cleave off the affinity tag of the purified fusion protein; the enzyme is obtained by purifying through 6 × His label (containing histidine label), the purity reaches 99%, and the enzyme can be removed through Ni affinity chromatography after the shearing reaction is finished. The optimum activity is achieved at pH7.0, 30 ℃ but TEV protease is active over a wide range of pH5.5-8.5 and 4-30 ℃ so that the choice of reaction conditions can be modified depending on the protein of interest.
One protease cleavage site useful in the present invention is TEV protease, shown in SEQ ID No. 3.
In addition, the N-terminus of the fusion protein of the present invention may or may not have a secretion signal peptide. When having a secretion signal peptide, it is helpful to achieve secretory expression of the fusion protein in order to improve purification efficiency. In the present invention, the secretion signal peptide to be used includes a secretion signal peptide derived from Slit2 or a secretion signal peptide derived from another protein introduced from an external source. Wherein, the nucleotide sequence of the secretion signal peptide from the Slit2 is shown in SEQ ID NO. 14, and the sequence of the coded signal peptide is shown in SEQ ID NO. 15.
Coding sequences and recombinant production
For the fusion protein of the present invention, the polynucleotide of the present invention may be in the form of DNA or in the form of RNA. The form of DNA includes cDNA, genomic DNA or artificially synthesized DNA. The DNA may be single-stranded or double-stranded. The DNA may be the coding strand or the non-coding strand.
The present invention also relates to variants of the above polynucleotides which encode protein fragments, analogs and derivatives having the same amino acid sequence as the present invention. The variant of the polynucleotide may be a naturally occurring allelic variant or a non-naturally occurring variant. These nucleotide variants include substitution variants, deletion variants and insertion variants. As is known in the art, an allelic variant is a substitution of a polynucleotide, which may be a substitution, deletion, or insertion of one or more nucleotides, without substantially altering the function of the encoded polypeptide.
As used herein, the term "primer" refers to a generic term for an oligonucleotide that, when paired with a template, is capable of synthesizing a DNA strand complementary to the template from its origin by the action of a DNA polymerase. The primer can be natural RNA, DNA, and any form of natural nucleotide. The primers may even be non-natural nucleotides such as LNA or ZNA etc. A primer is "substantially" (or "substantially") complementary to a particular sequence on one strand of the template. The primer must be sufficiently complementary to one strand of the template to begin extension, but the sequence of the primer need not be completely complementary to the sequence of the template. For example, a primer that is complementary to the template at its 3 'end and has a sequence that is not complementary to the template at its 5' end remains substantially complementary to the template. Primers that are not perfectly complementary can also form a primer-template complex with the template, so long as there is sufficient primer binding to the template, allowing amplification to occur.
The full-length nucleotide sequence of each element of the fusion protein of the present invention or a fragment thereof can be obtained by PCR amplification, recombination, or artificial synthesis. For the PCR amplification method, primers can be designed based on the disclosed nucleotide sequences, particularly open reading frame sequences, and the sequences can be amplified using a commercially available cDNA library or a cDNA library prepared by a conventional method known to those skilled in the art as a template. When the sequence is long, two or more PCR amplifications are often required, and then the amplified fragments are spliced together in the correct order.
Once the sequence of interest has been obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, transferring it into a cell, and isolating the relevant sequence from the propagated host cell by conventional methods.
In addition, the sequence can be synthesized by artificial synthesis, especially when the fragment length is short. Generally, fragments with long sequences are obtained by first synthesizing a plurality of small fragments and then ligating them.
A method of amplifying DNA/RNA using PCR technology is preferably used to obtain the gene of the present invention. The primers used for PCR can be appropriately selected based on the sequence information of the present invention disclosed herein, and can be synthesized by a conventional method. The amplified DNA/RNA fragments can be isolated and purified by conventional methods, such as by gel electrophoresis.
The invention also relates to vectors comprising the polynucleotides of the invention, as well as genetically engineered host cells encoded with the vector or fusion protein coding sequences of the invention, and methods of making the fusion proteins of the invention.
The polynucleotide sequences of the present invention may be used to express or produce recombinant proteins by conventional recombinant DNA techniques. Generally, the following steps are performed:
(1) transforming or transducing a suitable host cell with a polynucleotide (or variant) of the invention encoding a protein of the invention, or with a recombinant expression vector comprising the polynucleotide;
(2) a host cell cultured in a suitable medium;
(3) isolating and purifying the protein from the culture medium or the cells.
Methods well known to those skilled in the art can be used to construct expression vectors containing the DNA sequences encoding the proteins of the invention and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombinant techniques, and the like. The DNA sequence may be operably linked to a suitable promoter in an expression vector to direct mRNA synthesis. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.
Vectors comprising the appropriate DNA sequences described above, together with appropriate promoter or control sequences, may be used to transform appropriate host cells to enable expression of the protein.
The host cell may be a prokaryotic cell, such as a bacterial cell; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples are: coli, bacterial cells of the genus streptomyces; fungal cells such as yeast; a plant cell; insect cells of Drosophila S2 or Sf 9; CHO, COS, or 293 cell.
Transformation of a host cell with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. When the host is prokaryotic, e.g., E.coli, competent cells capable of DNA uptake can be harvested after exponential growth phase using CaCl2Methods, the steps used are well known in the art. Another method is to use MgCl2. If desired, transformation can also be carried out by electroporation. When the host is a eukaryote, the following DNA transfection methods may be used: calcium phosphate coprecipitation, conventional mechanical methods such as microinjection, electroporation, liposome encapsulation, etc.
The obtained transformant can be cultured by a conventional method to express the polypeptide encoded by the gene of the present invention. The medium used in the culture may be selected from various conventional media depending on the host cell used. The culturing is performed under conditions suitable for growth of the host cell. After the host cells have been grown to an appropriate cell density, the selected promoter is induced by suitable means (e.g., temperature shift or chemical induction) and the cells are cultured for an additional period of time.
The protein in the above method may be expressed intracellularly or on the cell membrane, or secreted extracellularly. If desired, the proteins can be isolated and purified by various separation methods using their physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of such methods include, but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (such as salt precipitation), centrifugation, cell lysis by osmosis, sonication, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, High Performance Liquid Chromatography (HPLC), and other various liquid chromatography techniques, and combinations thereof.
Expression vector
After the DNA sequence encoding the fusion protein of the present invention is obtained, it is ligated into a suitable expression vector and transferred into a suitable host cell. Finally, the fusion protein of the invention is obtained by culturing the transformed host cell and separating and purifying.
Thus, the invention also provides a vector comprising a nucleic acid molecule encoding the fusion protein. The vector may further comprise an expression control sequence operably linked to the sequence of the nucleic acid molecule to facilitate expression of the fusion protein.
As used herein, "operably linked" or "operably linked" refers to a condition in which certain portions of a linear DNA sequence are capable of affecting the activity of other portions of the same linear DNA sequence. For example, if the signal peptide DNA is expressed as a precursor and is involved in secretion of the polypeptide, the signal peptide (secretory leader) DNA is operably linked to the polypeptide DNA; if the promoter controls the transcription of a sequence, it is operably linked to the coding sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation. Generally, "operably linked" means adjacent, and for secretory leaders means adjacent in reading frame.
In the present invention, any suitable vector may be used, such as some vectors for cloning and expression of bacterial, fungal, yeast and mammalian cells, e.g., Pouwels et al, cloning vectors: described in a laboratory manual (latest edition of Elsevier). Various carriers known in the art such as commercially available carriers can be used. For example, a commercially available vector can be selected and the nucleotide sequence encoding the novel fusion protein of the present invention can then be operably linked to expression control sequences to form a protein expression vector.
One preferred eukaryotic expression vector useful in the present invention may be pcDNA3.1(-) (available from Invitrogen).
Expression vectors include fusion protein DNA sequences linked to appropriate transcriptional and translational regulatory sequences, such as genes derived from mammals, microorganisms, viruses, or insects. Regulatory sequences may include transcriptional promoters, operators, enhancers, ribosome binding sites, or suitable sequences that control transcription and translation initiation and termination. Where the fusion protein sequence requires regulatory sequence function, appropriate regulatory sequences are attached. Thus, the promoter sequence is ligated in front of the DNA sequence encoding the fusion protein. The ability to replicate in a host cell is generally controlled by the origin of replication. A selection gene for transformant identification may also be added to the expression vector.
In addition, the coding sequence of the signal peptide of the non-natural Slit2 protein can be introduced into an expression vector. For example: the signal peptide (secretion guide) sequence may be fused to the fusion protein coding sequence so that the translated fusion protein may be secreted extracellularly. The signal peptide may enhance secretion of the chimeric polypeptide extracellularly by the host cell. The signal peptide may be cleaved off during secretion of the polypeptide from the cell.
Method for producing Slit2LRR1-2 protein
The invention also includes a method for producing a fusion protein and a purified Slit2LRR1-2 protein, the method comprising culturing a host cell comprising a nucleic acid encoding the fusion protein, thereby culturing the fusion protein of the invention, and isolating and purifying the fusion protein of claim 1 from the culture system; and carrying out enzymolysis on the fusion protein by using protease aiming at the element E, thereby preparing the purified Slit2LRR1-2 protein.
When the tag elements of the fusion protein are separated, affinity chromatography aiming at different tag elements can be used for separation twice, and then protease aiming at enzyme cutting sites is used for enzymolysis, so that the Slit2LRR1-2 protein with higher purity can be separated.
The fusion protein comprises Slit2LRR1-2 or an active fragment thereof. The method can include allowing the cell to express the encoded fusion protein, and allowing renaturation of the expressed fusion protein. The method may further comprise isolation and/or purification of the renatured fusion protein.
The fusion protein prepared as described above can be purified to substantially uniform properties, for example, as a single band on SDS-PAGE electrophoresis. For example, when the recombinant protein is expressed for secretion, the protein can be isolated using commercially available ultrafiltration membranes, such as Millipore, Pellicon, etc., and the expression supernatant is first concentrated. The concentrated solution can be further purified by gel chromatography or ion exchange chromatography. Such as anion exchange chromatography (DEAE etc.) or cation exchange chromatography. The gel matrix can be agarose, dextran, polyamide, etc. commonly used for protein purification. The Q-or SP-group is preferably an ion exchange group. Finally, the purified product can be further refined and purified by hydroxyapatite adsorption chromatography, metal chelate chromatography, hydrophobic interaction chromatography, reversed phase high performance liquid chromatography (RP-HPLC), and the like.
The expressed fusion polypeptide can be purified by using affinity chromatography column containing specific antibody, receptor or ligand of Slit2LRR1-2 structural domain. The fusion polypeptide bound to the affinity column can be eluted by conventional methods, such as high salt buffer, pH change, etc., depending on the characteristics of the affinity column used.
The recombinant protein and the nucleic acid encoding the recombinant protein can be prepared by any suitable method, such as chemical synthesis, recombinant expression, or a combination thereof. See, e.g., Current protocols in Molecular Biology, John Wiley & Sons, Inc. 2000, and Molecular Conning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989.
The invention has the advantages of
1. The fusion protein of the invention has unique continuous tandem label element design, especially the improved Strap II label, has proper length, enables the expressed protein to be modified in various ways in host cells, can reduce the natural conformation of the expressed protein to the maximum extent under the condition of not influencing the protein folding, enables the Slit2LRR1-2 protein to be expressed in the host cells, and has high expression quantity and complete and accurate expression.
2. The design of the continuous series-connection label element of the fusion protein enables the target protein to be more easily purified, the label element can be completely cut off by one-time enzyme digestion, the preparation process is simple, and the prepared Slit2LRR1-2 protein is high in purity and strong in activity.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Experimental procedures without specific conditions noted in the following examples, generally followed by conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the Laboratory Manual (New York: Cold spring Harbor Laboratory Press,1989), or according to the manufacturer's recommendations. Unless otherwise indicated, percentages and parts are percentages and parts by weight.
Example 1 construction of pcDNA3.1(-)/Slit2LRR1-2 vector
The method comprises the following steps: construction of plasmids by exonuclease method. And (3) constructing a plasmid, amplifying 2 segments of fragments (a signal peptide sequence + a target sequence, an enzyme cutting site + a tag protein sequence) by using a PCR (polymerase chain reaction), and performing fragment connection and insertion for 2 times. The primers used were Primer1 and Primer2, respectively.
The exonuclease method comprises the following specific steps:
1. preparing a reaction system: 50ng each of the vector fragment (gel recovered and assayed after BamHI cleavage) and the PCR fragment (gel recovered and assayed after PCR) was supplemented with ddH and 1ul10x exonuclease buffer2O to 10 ul;
2. standing on ice for 5min, adding exonuclease III (Takara) diluted to 20U/ul at 1ul, mixing, and standing on ice for 60 min;
3. adding 1ul of 0.5M EDTA (pH8.0) solution to stop the reaction, and then carrying out water bath at 65 ℃ for 5 min;
4. placing on ice for 5min after water bath;
5. the ligation product is converted.
Primer:
Primer1-F：CCACACTGGACTAGTATGCGCGGCGTTGGCTGG SEQ ID NO.:8
Primer1-R：ACCGAGCTCGGATCCTTATGAACAACGGAATTTCTTG SEQ ID NO.:9
Primer2-F：AAATTCCGTTGTTCACTGGAAGTGCTGTTCCAG SEQ ID NO.:10
Primer2-R：ACCGAGCTCGGATCCTTAGTGGTGGTGGTGGTGGTG SEQ ID NO.:11
as a result: the amplification results of the target sequence, the restriction enzyme site + tag protein sequence are shown in FIGS. 3 and 4, which shows that the amplification of the signal peptide sequence + target sequence, restriction enzyme site + tag protein sequence is successful.
Example 2 successful expression of pcDNA3.1(-)/Slit2LRR1-2
The method comprises the following steps: to determine whether the constructed plasmid was successfully expressed, the plasmid was transfected into AD293 cells, followed by Western Blot via tag protein 8 × His to determine whether the fusion protein was successfully expressed.
Materials: high glucose DMEM medium and fetal bovine serum were purchased from Hyclone; transfection reagent Magetran was purchased from Origene; AD293 cells were cultured in High glucose DMEM medium containing 10% fetal bovine serum. The inverted microscope is an Olympus product, and the fluorescent inverted microscope is a Nikon product.
The method comprises the following steps:
2.1. and (4) resuscitating and culturing the frozen cells, carrying out passage for 3-4 times to enable the cells to reach a good growth state, and carrying out plate laying detection. The Magetran reagent transfects adherent cells.
2.2. AD293 cells were seeded into 6-well plates and cultured in High glucose DMEM medium containing 10% fetal bovine serum to a density of about 70% -80% for transfection. The Magetran reagent and the solution of plasmid pcDNA3.1(-)/Slit2LRR1-2 were equilibrated to room temperature and the following mixtures were prepared in a centrifuge tube: 200 mu of lopti-DMEM, 2 mu of plasmid and 6 mu of Magetran transfection reagent are shaken, mixed evenly and then kept stand for incubation for 10min at room temperature. After replacing the cells with new medium, the mixture was added to the culture dish and shaken up. Culturing in a 37 ℃ and 5% CO2 incubator for 12 hours, removing the culture medium, replacing with fresh High glucose DMEM culture medium containing 10% fetal calf serum to continue culturing, and after transfection for 48 hours, collecting protein for detecting the protein expression condition of the plasmid by Western Blot.
2.3 removing the culture medium, adding 4 ℃ PBS to scrape the cells off by using cells, putting the cells into a 1.5ml centrifuge tube, centrifuging for 5min after 2000 revolutions, and removing the supernatant. Then cell lysis is started, RIPA strong lysis solution and protease inhibitor are mixed according to the proportion of 100:1 and added into cell sediment, after shaking lysis is carried out for 1h at 4 ℃, centrifugation is carried out for 30min at 14000g at 4 ℃, and supernatant is taken, namely a sample. And finally, measuring the protein concentration of the sample, adding a Loading buffer, boiling for 8min, leveling, and carrying out gel running by SDS-polypropylene gel electrophoresis. Electrophoresis was performed for 3 hours, membrane transfer was performed for 2 hours, and then antibody incubation, first antibody incubation for 2 hours, and color development exposure was performed.
As a result: the Western Blot assay results are shown in FIG. 6. The histone expression of the transfection plasmid is normal, and the protein expression is not detected in the transfection no-load group, which shows that the constructed eukaryotic expression plasmid can be normally expressed in eukaryotic cells, and the plasmid construction is successful.
Example 3 measurement of expression amount
One of the purified HisGFP proteins was used as a control at a known concentration (20. mu.g/ml), and the amount of protein expressed was measured by the method of WesternBlot.
The specific method is the same as example 2, the cells are transfected first, and then Western Blot detection is carried out. The difference is that a known amount of HisGFP protein was added as a positive control during running SDS-PAGE.
And after exposure to obtain a result, calculating the expression quantity of the protein by carrying out gray level analysis on the strip.
Example 4 purification of Slit2LRR1-2 protein
The method and the material are as follows: because the adopted protein expression system is a high-efficiency mammalian expression system, the selected cells are optimized Chinese hamster ovary cells CHO-S widely used for protein expression, and extracellular secretion signal peptides are added into the expression vector, the suspension culture method is adopted, so that the cells secrete as much protein as possible into the culture solution under the condition of high density, and the culture solution is collected for subsequent protein purification.
The purification method comprises the following steps:
4.1, performing chromatography by using a biotin affinity column aiming at the first tag polypeptide element, and performing chromatography by using a Ni affinity column aiming at the second tag short peptide element; or
4.2 the chromatography is carried out by using a Ni affinity column aiming at the second label short peptide element, and then the chromatography is carried out by using a biotin affinity column aiming at the first label polypeptide element.
Firstly, quantifying the purified protein fragment, proportionally adding TEV protease for enzyme digestion, and removing the protein label.
Enzyme digestion buffer solution: 50mM Tris7.5, 500mM NaCl, 5% Glycerol, at 4 ℃ overnight.
The tag protein fragment and TEV protease in the enzyme-cleaved system can be removed by Ni affinity chromatography.
EXAMPLE 5 determination of purified Slit2LRR1-2
The method comprises the following steps: after purification to obtain the Slit2LRR1-2 protein, functional detection is carried out by adopting a cell biology experiment. Among them, the cell scratch test and the Transwell cell migration test were performed to preliminarily determine the function of protein.
The scratch test refers to an in vitro cell injury healing test model, scratches and injuries are caused on a monolayer cell cultured in vitro, and then a medicine is added to observe the capability of inhibiting the migration of tumor cells.
Digesting cells in logarithmic growth phase with pancreatin, and adjusting cell concentration to 2-10 × 105Each cell per ml, 500ul of cell suspension is added into each well of a 24-well plate, and the cell is cultured for 24 hours in a cell culture box at 37 ℃ so that the cells adhere to the wall. Scratching a single-layer cell by using a 10uL pipette tip (or a sterile toothpick), washing the single-layer cell for 3 times by using PBS (phosphate buffer solution), adding different solutions of Slit2LRR1-2 protein fragments (concentration gradient can be set) prepared by using a 2% FBS (FBS) culture medium, taking 3-4 parallel samples, and culturing the samples at 37 ℃ for 12-24 hours according to different invasion capacities of tumor cells. The area of cell migration was measured by taking a photograph under the mirror.
The Transwell cell migration assay mainly used 24-well plate chambers. The bottom membrane of the Transwell chamber (Millipore) was coated with collagen (collagen). Digesting cells, washing 1-2 times with PBS, resuspending cells in serum-free medium containing 0.2% BSA, adjusting cell density to 1-10X 10 after counting5200. mu.l of the cell suspension was taken and placed in a Transwell chamber, and 500. mu.l of serum-containing medium was added to the lower chamber of the 24-well plate, to which different fragments of Slit2LRR1-2 protein were added. Culturing at 37 deg.C for 12-48h according to the invasion capacity of tumor cells. The influence of the Slit2LRR1-2 protein fragment on the invasion capacity of the tumor cells is evaluated by using crystal violet stained cells and taking pictures under a microscope to count the number of the penetrated cells.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Claims (11)
1. A fusion protein having a structure according to formula Ia or Ib from N-terminus to C-terminus:
A-X-E-Y1-Y2 formula Ia;
A-Y2-Y1-E-X are of formula Ib;
wherein,
a is an optional secretion signal peptide;
x is a leucine-rich repeat1-2 (leucine-rich repeat1-2, LRR1-2) element of Slit2 protein;
e is a restriction enzyme site;
y1 is a first tag polypeptide element;
y2 is a second tag short peptide element which is a His tag element;
"-" denotes a peptide bond or a peptide linker connecting the above elements.
2. The fusion protein of claim 1, wherein Y1 comprises a modified avidin tag (Strap II tag) or a streptavidin tag (streptavidin) as set forth in SEQ ID No. 2.
3. The fusion protein of claim 1, wherein Y1 is a Strap II tag and Y2 is an 8 x His tag element.
4. The fusion protein of claim 1, wherein the Slit2LRR1-2 has an amino acid sequence as set forth in SEQ ID No. 5.
5. An isolated polynucleotide encoding the fusion protein of claim 1.
6. An expression vector comprising the polynucleotide of claim 5.
7. A host cell comprising the expression vector of claim 6 or transfected with the polynucleotide of claim 5.
8. The host cell of claim 7, wherein the host cell comprises a mammalian cell; preferably, CHO cells, 293 cells are included.
9. A method for preparing a Slit2LRR1-2 protein, which is characterized by comprising the following steps:
(i) culturing the host cell of claim 8 under suitable expression conditions to express the fusion protein of claim 1;
(ii) isolating and purifying the fusion protein of claim 1 from the culture system;
(iii) and carrying out enzymolysis on the fusion protein by using protease aiming at the element E to prepare Slit2LRR 1-2.
10. A method for preparing a Slit2LRR1-2 protein, which is characterized by comprising the following steps:
the fusion protein of claim 1, enzymatically cleaved with a protease directed against element E to produce Slit2LRR 1-2.
11. A purified Slit2LRR1-2 protein produced by the method of claim 9 or 10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310150884.4A CN104119445A (en) | 2013-04-26 | 2013-04-26 | Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310150884.4A CN104119445A (en) | 2013-04-26 | 2013-04-26 | Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104119445A true CN104119445A (en) | 2014-10-29 |
Family
ID=51765102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310150884.4A Pending CN104119445A (en) | 2013-04-26 | 2013-04-26 | Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104119445A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016179861A1 (en) * | 2015-05-11 | 2016-11-17 | 李华顺 | Slit2d2-hsa fusion protein and use thereof against tumours |
| CN106478783A (en) * | 2015-08-24 | 2017-03-08 | 北京大北农科技集团股份有限公司动物医学研究中心 | A kind of Porcine Circovirus genetic engineering subunit vaccine and its application |
| CN106589130A (en) * | 2015-10-14 | 2017-04-26 | 李华顺 | Slit2D2-HSA recombinant protein and application thereof in treatment of sepsis |
| WO2017177641A1 (en) * | 2016-04-15 | 2017-10-19 | 李华顺 | Slit2d2-chimeric antigen receptor and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101821283A (en) * | 2007-09-14 | 2010-09-01 | Scil技术股份有限公司 | Use of SLIT, NEPHRIN, ephrin or semaphorin for treatment of cartilage diseases |
-
2013
- 2013-04-26 CN CN201310150884.4A patent/CN104119445A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101821283A (en) * | 2007-09-14 | 2010-09-01 | Scil技术股份有限公司 | Use of SLIT, NEPHRIN, ephrin or semaphorin for treatment of cartilage diseases |
Non-Patent Citations (2)
| Title |
|---|
| CECILE MORLOT ET AL.,: "Production of Slit2 LRR domains in mammalian cells for structural studies and the structure of human Slit2 domain 3", 《ACTA CRYSTALLOGRAPHICA SECTION D》 * |
| URSULA SCHAFFER ET AL.,: "SnAvi－a new tandem tag for high-affinity protein-complex purification", 《NUCLEIC ACIDS RES》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016179861A1 (en) * | 2015-05-11 | 2016-11-17 | 李华顺 | Slit2d2-hsa fusion protein and use thereof against tumours |
| CN106279423A (en) * | 2015-05-11 | 2017-01-04 | 李华顺 | Slit2D2-HSA fusion protein and the application in antitumor thereof |
| US11041157B2 (en) | 2015-05-11 | 2021-06-22 | Huashun LI | Slit2D2-HSA fusion protein and use thereof against tumours |
| CN106279423B (en) * | 2015-05-11 | 2021-11-05 | 李华顺 | Slit2D2-HSA fusion protein and application thereof in tumor resistance |
| CN106478783A (en) * | 2015-08-24 | 2017-03-08 | 北京大北农科技集团股份有限公司动物医学研究中心 | A kind of Porcine Circovirus genetic engineering subunit vaccine and its application |
| CN106589130A (en) * | 2015-10-14 | 2017-04-26 | 李华顺 | Slit2D2-HSA recombinant protein and application thereof in treatment of sepsis |
| CN106589130B (en) * | 2015-10-14 | 2019-11-01 | 阿思科力(苏州)生物科技有限公司 | A kind of Slit2D2-HSA recombinant protein and its application in treatment pyemia |
| WO2017177641A1 (en) * | 2016-04-15 | 2017-10-19 | 李华顺 | Slit2d2-chimeric antigen receptor and application thereof |
| US11246888B2 (en) | 2016-04-15 | 2022-02-15 | Asclepius (Suzhou) Technology Company Group Co., Ltd. | Slit2D2-chimeric antigen receptor and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7382383B2 (en) | Producer cell line enhancer | |
| EP1811023A1 (en) | Gene expressed specifically in es cells and utilization of the same | |
| CA2353086A1 (en) | Pgc-1, a novel brown fat ppar.gamma. coactivator | |
| CN110577592B (en) | Recombinant human fibronectin peptide | |
| CN114805551A (en) | Recombinant type III collagen and preparation method thereof | |
| CN105683216B (en) | Human EGF structural domain protein and application thereof | |
| CN104119445A (en) | Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof | |
| Li et al. | Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing | |
| JP4604184B2 (en) | Novel sugar chain recognition protein and its gene | |
| CN106754817B (en) | Expression method of recombinant autotaxin | |
| CN104119447A (en) | Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof | |
| CN104119448A (en) | Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof | |
| CN112538494A (en) | TMPRSS2 mutant protein, expression vector, expression engineering bacterium and preparation method thereof | |
| CN104119446A (en) | Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof | |
| CN114380920B (en) | Human alpha fetoprotein fusion protein, and preparation method and application thereof | |
| AU2021351946B2 (en) | Cell culture process for producing rsv f protein | |
| WO2019143193A1 (en) | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same | |
| CN112662676A (en) | Method for coding polypeptide or protein of target hydrolyzed protein by DNA | |
| CN101775404A (en) | Method for highly expressing basic protein with prokaryotic expression system | |
| CN105198999A (en) | Fusion protein and its preparation method and use | |
| US20100021997A1 (en) | Biologically active recombinant human saposin C and PSAP | |
| CN106337043B (en) | People's trypsin mutant of high stability | |
| CN109384838B (en) | Triple transcription factor and application thereof in mammalian protein expression system | |
| KR101841646B1 (en) | Method for the preparation of AIMP2-DX2 as a target for anti-cancer drug discovery | |
| CN116396395A (en) | Human transferrin fusion protein and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141029 |
|
| RJ01 | Rejection of invention patent application after publication |